Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 déc. 2016 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces USPTO Grants Patent for Paclitaxel PDC; Provides Additional Patent Protection for Select Solid Tumors Through 2035

MADISON, Wis., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused clinical stage biotechnology company, today announced that the...
06 déc. 2016 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Presents Poster at the 58th Annual Meeting of the American Society of Hematology

MADISON, Wis., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announced that it...
01 déc. 2016 08h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Results From the First Two Cohorts of Its CLR 131 Phase 1 Trial: Demonstrates Excellent Efficacy, Overall Survival Benefit, and Progression Free Survival Similar to or Better than Recently Approved Therapies

MADISON, Wis., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today provides a data update...
29 nov. 2016 18h40 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Successful Completion of $9.2 Million Public Offering, Which Includes Full Exercise of $1.2 Million Over-Allotment Option

MADISON, Wis., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) ("Cellectar" or the "company"), an oncology-focused, clinical stage biotechnology company, today...
28 nov. 2016 08h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Partnership with Radiopharmaceutical Specialists, CPDC, to Establish Manufacturing Capacity in Anticipation of CLR 131 Pivotal Trial and Commercial Production

MADISON, Wis., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announced it has...
23 nov. 2016 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Pricing of $8,000,000 Public Offering

MADISON, Wis., Nov. 23, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) ("Cellectar" or the "company"), an oncology-focused, clinical stage biotechnology company, today...
17 nov. 2016 08h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Successful Conjugation of Multiple Pierre Fabre Cytotoxic Compounds to PDC Delivery Platform; Initiates In Vivo Studies for Solid Tumors

MADISON, Wis., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces that...
15 nov. 2016 10h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces INC Research as the CRO for the Phase II Trial of CLR 131 in Hematologic Malignancies; $2M NCI Grant Covers Half of Study Cost, with Potential Option to Pursue Additional $3M for Pivotal Trial

MADISON, Wis., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announced it has...
11 nov. 2016 13h50 HE | Source: Cellectar Biosciences, Inc.

UPDATE -- Cellectar Biosciences Announces Recent Key Accomplishments and Third Quarter 2016 Financial Results

MADISON, Wisc., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces key...
10 nov. 2016 16h15 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Recent Key Accomplishments and Third Quarter 2016 Financial Results

MADISON, Wisc., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces key...

Page précédente